Acceptance code: EE303

Adult Immunisation with Tetanus, Diphtheria, and Pertussis Vaccine for At-Risk Populations (Asthma, COPD, HIV) for the Prevention of Pertussis in Colombia

Nurilign Ahmed¹, Edisson Rodriguez², Victor Saravia², Laura Triana², Jorge A. Gomez³

¹GSK, Wavre, Belgium, ²GSK, Bogota, Colombia, ³GSK, Buenos Aires, Argentina



 Pertussis (i.e. whooping cough) infection in at-risk adults with pre-existing conditions, is associated with high rates of hospitalisation and increased healthcare resource utilisation (HCRU)¹⁻³

 While children and adolescents are typically vaccinated against pertussis, immunity wanes over time⁴



Pertussis cases, outpatient complications and hospitalisations

Figure 1: Pertussis-related health outcomes with and without Tdap entry as a booster

A) Pertussis cases

Conclusions



Introducing Tdap vaccination for 20-year-old adults with asthma, COPD, or HIV in Colombia at just 10% coverage could substantially decrease pertussis disease burden and associated HCRU



A proportion of the healthcare insurance plan budget would be required to protect those at risk



Digital poster



B) Outpatient pertussis cases with complications C) Pertussis-related hospitalisations


 Tetanus, diphtheria, and pertussis (Tdap) booster vaccination has been shown to be an effective and safe method to prevent pertussis in at-risk populations, including those with asthma, chronic obstructive pulmonary disease (COPD) and human immunodeficiency virus (HIV), but is currently only recommended for those with HIV in Colombia⁵

Aims

To estimate the 5-year budgetary impact, from the payer's perspective, of introducing Tdap booster vaccination for at-risk adults with asthma, COPD and HIV into Colombia's healthcare insurance plan

Methods

A Microsoft Excel-based model was developed to estimate the budgetary impact over 5 years (2025–2029) of administering 1 dose of Tdap booster to 20-year-old adults with asthma, COPD or HIV in Colombia. Costs are expressed in 2023 United States Dollar (USD \$)



- Assuming just 10% coverage, introducing Tdap for patients with asthma, COPD and HIV could avert 135, 103 and 50 pertussis cases, 13, 10 and 5 outpatient
 pertussis cases with complications and 8, 9 and 3 pertussis-related hospitalisations over 5 years, respectively (Figure 1)
- Without Tdap, there would be an estimated 12, 9 and 3 pertussis-related deaths for asthma, COPD and HIV, respectively. With Tdap, no deaths were
 predicted to be avoided

Cost and budget impact

- Over 5 years, with 10% Tdap immunisation coverage (Figure 2, Table 1)
 - Estimated immunisation costs were \$1.5 M for asthma (99 K doses), \$1.5 M for COPD (102 K doses) and \$291 K for HIV patients (20 K doses)
 - Estimated savings in pertussis disease management costs were \$142 K for asthma, \$165 K for COPD and \$46.3 K for HIV
 - Estimated savings in costs for treatment of exacerbations of underlying conditions were \$7.7 K for asthma, \$80.8 K for COPD and \$107 K for HIV
- The total budget impact of introducing Tdap over 5 years was predicted to be \$1.3 M, \$1.2 M and \$0.1 M for these conditions (Figure 2, Table 1)

Figure 2: Total budget impact of Tdap entry as a booster into Colombia's healthcare insurance plans

A) Total medical costs associated with pertussis B) Total costs associated with treating underlying conditions

C) Total budget impact of introducing Tdap

In the base case, the model assumed a 10% vaccination coverage⁶ with a 74% Tdap market share

Age distribution was taken from population pyramids reported by the United Nations Department of Economic and Social Affairs in 2021,⁷ and annual population growth was obtained from the World Bank Group⁸

Pertussis incidence was based on those reported in Brazil between 2011 and 2012.⁹ Asthma, COPD and HIV prevalence data were based on cross sectional studies in Colombia^{10–12}

Costs associated with treating underlying conditions were sourced from three cost-of-illness studies of each disease in Colombia^{13–15}




Table 1: Total budget impact of Tdap entry as a booster into Colombia's healthcare insurance plans, by year

	Incremental cost, USD ^a				
	Year	Vaccination	Pertussis disease management	Treatment of underlying conditions	Total budget impact
Asthma	1	284,542.31	-27,753.33	-1,497.29	255,291.70
	2	287,672.28	-28,058.61	-1,513.76	258,099.90
	3	290,836.67	-28,367.26	-1,530.41	260,939.00
	4	294,035.88	-28,679.30	-1,547.25	263,809.33
	5	297,270.27	-28,994.77	-1,564.27	266,711.23
	Total	1,454,357.42	-141,853.27	-7,652.98	1,304,851.17
COPD	1	291,139.16	-32,195.27	-15,817.19	243,126.71
	2	294,341.69	- 32,549.41	-15,991.18	245,801.10
	3	297,579.45	-32,907.46	-16,167.08	248,504.91
	4	300,852.83	-33,269.44	-16,344.92	251,238.47
	5	304,162.21	-33,635.40	-16,524.71	254,002.09
	Total	1,488,075.34	-164,556.98	-80,845.08	1,242,673.28
HIV	1	56,885.05	-9,052.39	-20,937.92	26,894.74
	2	57,510.79	-9,151.97	-21,168.24	27,190.58
	3	58,143.41	-9,252.64	-21,401.09	27,489.68
	4	58,782.99	-9,354.42	-21,636.50	27,792.06
	5	59,429.60	-9,457.32	-21,874.50	28,097.77
	Total	290,751.83	-46,268.74	-107,018.26	137,464.83



Vaccine-related and pertussis-related disease management costs were calculated based on 2023 pricing data from the Colombian health system database, SISPRO^{16–17}

A scenario analysis is also presented where the market share of Tdap was increased to 100%

[a] Incremental cost was calculated by subtracting the cost without Tdap entry from the cost with Tdap entry

Scenario analysis

• The scenario analyses estimated a total budget impact of \$1.8 M, \$1.7 M and \$0.2 M for asthma, COPD and HIV patients respectively (~35% increase)

Abbreviations References

COPD, chronic obstructive pulmonary disease; HCRU, healthcare resource utilisation; HIV, human immunodeficiency virus; K, thousand; M, million; Tdap, tetanus, diphtheria, and pertussis vaccine; USD, United States dollar

1. Macina, D et al. Infect Dis Ther 2021;10(3):1141–1170 2. Jenkins VA et al. Hum Vaccin Immunother 2020;16(11):2609–2617 3. Buck PO et al. Epidemiol Infect 2017;145(10):2109–2121 4. Burdin N et al. Cold Spring Harb Perspect Biol 2017;9(12)a029454 5. Casey JR et al. Drugs 2005; 65(10):1367–89 6. Minsalud. Sistema de información de Precios de Medicamentos (SISMED). Analysis Services: "2019Q1-2023Q3". Available at: https:// cubos.sispro.gov.co (Accessed: April 2024) 7. United Nations Department of Economic and Social Affairs. Population Division. World Population Prospects 2021. Available at: https://population.un.org/wpp/Download/ Standard/Population (Accessed: October 2024) 8. World Bank Group. Population growth (annual %) - Colombia. Available at: https://data.worldbank.org/indicator/SP.POP.GROW?locations=CO (Accessed: October 2024) 9. Guimaraes, LM et al. BMC Infect Dis 2015;15:442 10. Dennis, R et al. BMC Pulm Med 2012;12:17 11. Cardona-Arias, JA et al. HIV AIDS (Auckl) 2020;12:381-391 12. Caballero, A et al. Chest 2008;133(2):343-349; 13. Kuhlmann, J et al. Value Health Reg Issues 2017;14:103–107 14. Gil-Rojas, Y et al. Value Health Reg Issues 2024;39:6–13 15. Celis-Preciado, C et al. Value Health 2020;23:S349–S350 16. Minsalud. Estudio de Suficiencia de la UPC. MSOLAP 2021. Available at: https://cubos.sispro.gov.co/ (Accessed: October 2024) 17. Banrep. Índice de precios al consumidor (IPC) 2023. Available at: totoro.banrep.gov.co (Accessed: October 2024)

Disclosures

Acknowledgements Funding

NA and JG: employee of,
and hold financial equities in
GSK; ER and VS: employee
of GSK; LT: employee of GSK
and shareholder of SanofiThe authors thank May-Li MacKinnon,
Costello Medical, UK for medical writing
assistance and publication coordination,
and the Costello Medical Creative team
for design support, funded by GSK

This study (VEO-000738) and all costs associated with publication on, development, were funded by GSK

ISPOR Europe 2024 | 17–20 November 2024 | Barcelona, Spain

Presenting author: Nurilign Ahmed, nurilign.x.ahmed@gsk.com

